Sandbox R.Nithin 6XWD: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Racha Nithin (talk | contribs) No edit summary |
Racha Nithin (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
SARS-CoV-2 Main Protease (Mpro) – Structure and Covalent Inhibition (PDB: 6XWD) = | |||
This page provides structural overview of the SARS-CoV-2 main protease (Mpro), | This page provides structural overview of the SARS-CoV-2 main protease (Mpro), | ||
based on the iScience 2020 study (DOI: https://doi.org/10.1016/j.isci.2020.101258) and the | based on the iScience 2020 study (DOI: https://doi.org/10.1016/j.isci.2020.101258) and the | ||
| Line 5: | Line 5: | ||
In this study , the researchers produced SARS-CoV-2 Nsp9 in the lab and sloved its X-ray crystal structure | In this study , the researchers produced SARS-CoV-2 Nsp9 in the lab and sloved its X-ray crystal structure | ||
== Introduction == | == Introduction == | ||
| Line 25: | Line 24: | ||
Mpro functions as a homodimer, and each protomer is organized into three domains. | Mpro functions as a homodimer, and each protomer is organized into three domains. | ||
Domain I (residues 8–101) consists of a β-barrel-like scaffold that forms part of thecatalytic cleft and positions His41 of the catalytic dyad. | Domain I (residues 8–101) consists of a β-barrel-like scaffold that forms part of thecatalytic cleft and positions His41 of the catalytic dyad.The central domain of Nsp9 is composed of seven β-strands that fold into an oblong β-barrel structure 1 | ||
This β-barrel acts as the main stabilizing framework of the protein and is responsible for maintaining the shape and rigidity necessary for function. Because this fold is nearly identical across SARS-CoV and SARS-CoV-2, it suggests that the structural design is crucial for maintaining viral replication efficiency 2 | |||
Domain I is built mainly from antiparallel β-strands arranged into a β-barrel–like fold. | Domain I is built mainly from antiparallel β-strands arranged into a β-barrel–like fold. | ||
This domain forms one half of the active site cleft, and it holds His41, which is part of the catalytic dyad. | This domain forms one half of the active site cleft, and it holds His41, which is part of the catalytic dyad. | ||
| Line 55: | Line 55: | ||
Thus, Domain III functions as the activation switch of the protease by enabling dimer formation and structural locking.Its interactions with the opposite protomer stabilize the active conformation of the enzyme. Because Mpro activity depends on dimerization, Domain III indirectly controls catalytic function. Overall, the coordinated architecture of these three domains enables Mpro to recognize, bind, and cleave viral substrates with high specificity. | Thus, Domain III functions as the activation switch of the protease by enabling dimer formation and structural locking.Its interactions with the opposite protomer stabilize the active conformation of the enzyme. Because Mpro activity depends on dimerization, Domain III indirectly controls catalytic function. Overall, the coordinated architecture of these three domains enables Mpro to recognize, bind, and cleave viral substrates with high specificity. | ||
| Line 76: | Line 69: | ||
Together, the catalytic dyad, oxyanion hole, and surrounding pockets form a tightly coordinated active-site architecture that ensures high specificity and efficiency in viral polyprotein processing. | Together, the catalytic dyad, oxyanion hole, and surrounding pockets form a tightly coordinated active-site architecture that ensures high specificity and efficiency in viral polyprotein processing. | ||
The 6XWD structure captures Mpro bound to a covalent peptide-like inhibitor, revealing how the active site accommodates small-molecule or peptide-based antiviral compounds. The inhibitor occupies the **S1**, **S2**, and **S4** substrate-binding pockets that are formed at the interface of Domain I and Domain II. | The 6XWD structure captures Mpro bound to a covalent peptide-like inhibitor, revealing how the active site accommodates small-molecule or peptide-based antiviral compounds. The inhibitor occupies the **S1**, **S2**, and **S4** substrate-binding pockets that are formed at the interface of Domain I and Domain II. | ||